autologous bihaptenized cervical cancer vaccine

The autologous bihaptenized cervical cancer vaccine is an experimental immunotherapy developed by Avax Technologies. It utilizes the patient's own tumor cells, which are harvested, inactivated, and chemically modified with two haptens: dinitrophenyl (DNP) and sulfanilic acid. This 'bihaptenization' process is intended to make the tumor cells appear more foreign to the patient's immune system, thereby overcoming the immune tolerance that often allows cancer to grow unchecked. When administered intradermally, typically alongside the adjuvant BCG (Bacillus Calmette-Guérin), the vaccine stimulates the production of tumor-specific cytotoxic T-lymphocytes. These T-cells then circulate throughout the body to identify and destroy remaining cancer cells that express the same tumor-associated antigens. The vaccine has been primarily investigated in Phase I and Phase II clinical trials for patients with advanced, recurrent, or persistent cervical carcinoma.

Other names

DNP-sulfanilic acid-modified autologous cervical cancer vaccinebihaptenized autologous tumor cell vaccine